Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1728117 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.21Day +0.78%Mkt cap $49M1Y −89.5%Off 52W high −94.7%Vol (1Y) 140.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,872 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest31.2% of sh out |
| Days to cover3.8d |
| 13F net flow (QoQ)−3.17% |
| Top-10 13F concentration52.7% |
| Next report (est.)2026-08-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$55.5M |
| Earnings (TTM)-$180.4M |
| Net margin−351.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−93.3% |
| 1Y−89.5% |
| 3Y−84.7% |
| 5Y−97.4% |
| Since incept. (ann.)−45.0% |
Total return through 2026-07-29 · series begins 2019-02-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)140.9% |
| Ann. volatility (3Y)107.9% |
| Sharpe (1Y)−0.57 |
| Sharpe (3Y)0.12 |
| Max drawdown (1Y)−96.4% |
| Max drawdown (3Y)−96.4% |
| Beta (3Y vs SPY)3.09 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Kalehua Capital Management LLC | 17.7M | $6M | 7.55% | new |
| BlackRock, Inc. | 16.8M | $6M | 7.17% | −1.3% |
| AQR CAPITAL MANAGEMENT LLC | 10.1M | $3M | 4.31% | +804.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.4M | $3M | 4.00% | new |
| ARCH Venture Management, LLC | 8.1M | $3M | 3.43% | +0.0% |
| Octagon Capital Advisors LP | 7.8M | $3M | 3.30% | −44.3% |
| SAMSARA BIOCAPITAL, LLC | 7.2M | $2M | 3.08% | +0.0% |
| Balyasny Asset Management L.P. | 5.9M | $2M | 2.52% | +290.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.20 | — | $17.0M | +71.5% |
| 2025-12-31 | 2026-03-17 | — | — | $13.8M | +47.1% |
| 2025-09-30 | 2025-11-05 | −$0.21 | — | $13.3M | +40.2% |
| 2025-06-30 | 2025-08-05 | −$0.17 | −177.3% | $11.5M | −88.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-15 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reporting 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
